A5024325916- Liver Disease Diagnosis and Treatment
- Hepatitis C virus research
- Hepatitis B Virus Studies
- Hepatocellular Carcinoma Treatment and Prognosis
- HIV/AIDS drug development and treatment
- Systemic Lupus Erythematosus Research
- Liver Disease and Transplantation
- MRI in cancer diagnosis
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Liver Diseases and Immunity
- Pancreatic and Hepatic Oncology Research
- Renal cell carcinoma treatment
- Diet, Metabolism, and Disease
- Chronic Lymphocytic Leukemia Research
- Hepatitis Viruses Studies and Epidemiology
- Diabetes Treatment and Management
- Alcohol Consumption and Health Effects
- Pancreatitis Pathology and Treatment
- Cancer Mechanisms and Therapy
- Cancer, Lipids, and Metabolism
- Cancer Treatment and Pharmacology
- Lung Cancer Treatments and Mutations
- MicroRNA in disease regulation
- Radiomics and Machine Learning in Medical Imaging
- Cancer survivorship and care
Toranomon Hospital
2016-2025
Tokyo Denki University
2024
Inova Fairfax Hospital
2017
Chemotherapy Foundation
2016
St. Luke's International Hospital
2013-2016
Life Science Institute
2013
National Institute of Public Health
2013
St. Luke's International University
2013
Cambridge University Press
2011
New York University Press
2011
Chronic hepatitis B virus (HBV) infection leads to cirrhosis and hepatocellular carcinoma (HCC). Antiviral agents are thought reduce HCC development, but such as lamivudine (LAM) have a high rate of drug resistance. We compared the incidence in 472 entecavir (ETV)-treated patients 1,143 nontreated HBV (control group). Propensity score matching eliminated baseline differences, resulting sample size 316 per cohort. The mutation resistance was 0.8% (4/472) ETV group. cumulative rates at 5 years...
The aim of this study was to determine the incidence and risk factors hepatocellular carcinoma (HCC), elucidate utility two non-invasive predictive procedures for liver fibrosis: aspartate aminotransferase (AST) platelet ratio index (APRI) BARD score (which includes following three variables: body mass index, AST/alanine ratio, diabetes) in prediction HCC a large population Japanese patients with non-alcoholic fatty disease (NAFLD).This retrospective cohort conducted at public hospital....
Genetic variation near the IL28B gene and substitution of amino acid (aa) 70 91 in core region hepatitis C virus (HCV) genotype 1b can predict response to pegylated interferon (PEG-IFN)/ribavirin combination therapy, but its impact on triple therapy telaprevir/PEG-IFN/ribavirin is not clear. The aims this study were investigate predictive factors sustained virological a 12-week or 24-week regimen 72 81 Japanese adults infected with HCV 1. Overall, end-of-treatment achieved by 61% 89%,...
<b><i>Introduction:</i></b> Transarterial chemoembolization (TACE) is the standard treatment for unresectable intermediate-stage hepatocellular carcinoma (HCC), but recurrence after TACE common. The present phase 2, prospective, multicenter, single-arm trial, TACTICS-L investigated efficacy and safety of plus lenvatinib (LEN), a drug that more strongly promotes vascular normalization has better objective response rate (ORR) than sorafenib (jRCTs031180074)....
<i>Objective:</i> Patients with high titer (≧100 kIU/ml) of hepatitis C virus (HCV) genotype 1b do not achieve highly sustained virological response rates to combination therapy interferon plus ribavirin. Non-virological responders (NVRs, namely ultimate resistant cases) who HCV-RNA negativity during treatment are also encountered. We investigated the pretreatment features NVRs. <i>Methods:</i> evaluated 50 consecutive Japanese adults HCV received for 48 weeks....
Diabetes is present in patients with chronic hepatitis C virus infection. The aim of this retrospective cohort study was to assess the cumulative development incidence and predictive factors for type 2 diabetes after termination interferon therapy Japanese positive (HCV). A total 2,842 HCV-positive treated (IFN) monotherapy or combination IFN ribavirin were enrolled. mean observation period 6.4 years. An overnight (12-hour) fasting blood sample a casual taken routine analyses during...
The aim of this retrospective cohort study was to assess the cumulative development incidence and predictive factors for malignancies after termination interferon (IFN) therapy in Japanese patients hepatitis C virus (HCV). A total 4,302 HCV-positive treated with IFN were enrolled. mean observation period 8.1 years. primary outcome first onset malignancies. Evaluation performed using Kaplan-Meier method Cox proportional hazard analysis. 606 developed malignancies: 393 hepatocellular carcinoma...
The aim of this study was to assess the rate development hepatocellular carcinoma (HCC) in patients who achieved sustained virologic response (SVR) by direct antiviral agents (DAA). We retrospectively evaluated SVR oral DAA interferon-free regimens (n = 77) (daclatasvir/asunaprevir [n 67], ombitasvir/paritaprevir/ritonavir 9], and telaprevir 1]) pegylated-interferon plus ribavirin (Peg-IFN/RBV, n 528). In all patients, background chronic hepatitis or cirrhosis caused HCV genotype 1b. During...
A prospective study based on serial liver biopsies was performed to investigate the efficacy of sodium-glucose cotransporter 2 inhibitor for nonalcoholic fatty disease complicated with type diabetes mellitus. Conclusion: Treatment 24 weeks resulted in improvement histopathologic features all 5 patients. (Hepatology Communications 2017;1:46-52).
The aim of this study was to investigate the therapeutic potential sodium glucose cotransporter 2 inhibitor (SGLT2I) as an effective option for non-alcoholic fatty liver disease (NAFLD).In prospective study, nine patients with NAFLD complicated by type diabetes mellitus (DM), were introduced regimen canagliflozin 100 mg once daily 24 weeks and evaluated histology at pretreatment after start treatment. primary outcome histological improvement, defined a decrease in activity score one point or...
Abstract The aim of this study was to determine the impact at 5 years sodium‐glucose cotransporter 2 inhibitor (SGLT2i) in nonalcoholic fatty liver disease (NAFLD) with type diabetes mellitus (T2DM) on histopathology and clinical features. In retrospective study, histological impacts after start SGLT2i NAFLD T2DM were investigated. Six patients treated for long term canagliflozin SGLT2i, biopsies obtained points pretreatment, 24 weeks, 3 years, treatment. primary outcome histopathological...
Abstract BACKGROUND Advances in imaging technology have enhanced the detection of small nodular lesions during course chronic liver disease. METHODS Between 1995 and 2002, authors examined 154 consecutive patients with hepatic nodules without hepatocellular carcinoma (HCC) over a median duration 2.8 years. The size these was 14 mm (range, 7–40 mm). initial histopathologic diagnosis included high‐grade dysplastic nodule (HGDN) ( n = 13), low‐grade (LGDN) 42), regenerative (RN) 99). RESULTS A...
We showed previously that amino acid (aa) substitutions in hepatitis C virus core region (HCV-CR) are negative predictors of virologic response to pegylated interferon (IFN) plus ribavirin therapy. HCV-CR induces hepatocellular carcinoma transgenic mice, but the clinical impact is still unclear. To evaluate aa on hepatocarcinogenesis, we performed a follow-up study 313 noncirrhotic consecutive naïve patients infected with HCV genotype 1b who received IFN monotherapy. The median was 14.7...
Abstract For chronic hepatitis C virus (HCV) infection, evaluation of response to peginterferon (PEG‐IFN) plus ribavirin (RBV) therapy based on viral kinetics is useful as an early predictor treatment efficacy, but the underlying mechanisms different are still unclear. The 48‐week PEG‐IFN‐RBV combination was evaluated in 160 Japanese adult patients infected with HCV genotype 1b and determined rapid virological (at 4 weeks), 12 end‐of response, sustained (6 months after end treatment)....